Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study

被引：0
|
作者：
Strand, Vibeke [1 ]
Purcaru, Oana [2 ]
van Vollenhoven, Ronald F. [3 ]
Choy, Ernest [4 ]
Fleischmann, Roy [5 ]
机构：
[1] Stanford Univ, Portola Valley, CA USA
[2] UCB Pharma, Brussels, Belgium
[3] Karolinska Inst, Stockholm, Sweden
[4] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales
[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1318
引用
收藏
页码：S567 / S567
页数：1
相关论文
共 50 条
  • [31] Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease
    Haraoui, Boulos
    Bykerk, Vivian P.
    van Vollenhoven, Ronald
    de Longueville, Marc
    Luijtens, Kristel
    Ralston, Pauline
    Kavanaugh, Arthur
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S199 - S199
  • [32] LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
    van der Heijde, D.
    Braun, J.
    Rudwaleit, M.
    Landewe, R.
    Purcaru, O.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 809 - 809
  • [33] Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+Year Results of a 5-Year, Open-Label Extension Study
    Ashina, M.
    Goadsby, P. J.
    Reuter, U.
    Silberstein, S. D.
    Dodick, D. W.
    Chou, D. E.
    Klatt, J.
    Xue, F.
    Zhang, F.
    Cheng, S.
    Mikol, D. D.
    HEADACHE, 2019, 59 : 25 - 25
  • [34] INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES THAN WITH EITHER MONOTHERAPY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: 8-YEAR RESULTS OF AN OPEN-LABEL EXTENSION OF A PHASE 3 TRIAL
    Breedveld, Ferdinand
    Keystone, Edward
    van der Heijde, Desiree
    Landewe, Robert
    Smolen, Josef S.
    Guerette, Benoit
    McIlraith, Melissa
    Kupper, Hartmut
    Liu, Shufang
    Kavanaugh, Arthur
    RHEUMATOLOGY, 2012, 51 : 118 - 119
  • [35] Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial
    Breedveld, Ferdinand C.
    Keystone, Edward
    van der Heijde, Desiree
    Landewe, Robert
    Smolen, Josef
    Guerette, Benoit
    McIlraith, Melissa
    Kupper, Hartmut
    Liu, Shufang
    Wolfe, Benjamin
    Kavanaugh, Arthur
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S481 - S481
  • [36] LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
    van der Heijde, D.
    Braun, J.
    Rudwaleit, M.
    Landewe, R.
    Purcaru, O.
    Kavanaugh, A.
    VALUE IN HEALTH, 2016, 19 (07) : A546 - A546
  • [37] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
  • [38] A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (final 5-year data)
    Klareskog, L
    Wajdula, J
    Pedersen, R
    Yeh, P
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 254 - 254
  • [39] Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
    Yagoda, Sergey
    Graham, Christine
    Simmons, Adam
    Arevalo, Christina
    Jiang, Ying
    McDonnell, David
    CNS SPECTRUMS, 2021, 26 (04) : 383 - 392
  • [40] Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
    Thase, Michael E.
    Stanford, Arielle D.
    Memisoglu, Asli
    Martin, William
    Claxton, Amy
    Bodkin, J. Alexander
    Trivedi, Madhukar H.
    Fava, Maurizio
    Yu, Miao
    Pathak, Sanjeev
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (13) : 2268 - 2276
12345